AU Patent

AU2019289110B2 — GIP/GLP1 agonist compositions

Assigned to Eli Lilly and Co · Expires 2022-10-06 · 4y expired

What this patent protects

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

USPTO Abstract

A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019289110B2
Jurisdiction
AU
Classification
—
Expires
2022-10-06
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.